The current view is that the financing of R&D for neglected diseases should be provided by the public sector, while R&D itself is best carried out by the private pharmaceutical sector. In response to this model, most current policy proposals are aimed at mobilising substantial public finances to commercialise the neglected disease market, thereby allowing it to compete in company R&D priorities...

1 Parke-Davis Pharmaceutical Research, Ann Arbor, MI, 2 Stadtlander Drug Company Inc., and University of Pittsburgh, Pittsburgh, PA, 3 Ohio State University, Columbus, OH, 4 University of Wisconsin Hospitals & Clinics, Southfield, MI, 5 University of Arizona College of Pharmacy, Tucson, AZ, 6 Indiana University, Bloomington, IN, 7 Merck Research Laboratories, Blue Bell, PA, 8 University of Sout...

Letters from Silas Burroughs to his junior partner Henry Wellcome and other business associates have recently come to light Written during his travels (1880-1882) soon after the establishment of their pharmaceutical company, the letters show how this energetic, resourceful and imaginative salesman developed and expanded the business overseas and tackled the problems of preservation, packaging a...

3 J Clin Psychiatry 2006;67 (suppl 10) From the Department of Psychiatry, Medical University of South Carolina, Charleston. This article was supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. Corresponding author and reprints: Jacobo Mintzer, M.D., Department of Psychiatry, Medical University of South Carolina, 171 Ashley Ave...

Mika Murabayashi1, Taku Sugita1, Keiko Hirakawa2,3, Hideto Kuribayashi4, Ikuo Mori1, Kazuki Kubo1, Takashi Horiguchi1, Masayuki Ueda2,5, Yasuo Katayama2,5 and Youkichi Ohno2,3 Takeda Pharmaceutical Company Limited NMR and Small Animal MRI Laboratory, Nippon Medical School Department of Legal Medicine, Nippon Medical School Varian Technologies Japan Ltd. Division of Neurology, Department of Inte...

TAKESHI NIKAWA, MADOKA IKEMOTO, KAORI TOKUOKA, SHIGETADA TESHIMA, DAVID H. ALPERS, YOSHIHIRO MASUI, KYOICHI KISHI, AND KAZUHITO ROKUTAN Department of Nutrition, School of Medicine, University of Tokushima, Tokushima 770-8503, Japan; Department of Internal Medicine, Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri 63110; and Therapeutic Application Deve...

The legal opinion article by Sam Rowlands in the April 2012 issue of this Journal raises important issues but I would like to correct the statement regarding the licensing of mifepristone in New Zealand and Australia. The two countries have an entirely different history regarding the licensing of mifepristone. In New Zealand in 1999 a group of doctors formed a not-for-profit pharmaceutical comp...

the purpose of this paper is to make explicit how companies in pharmaceutical sector can ensure their position in different markets by relying on a sustainable competitive advantages resulted from using a good defined marketing model. various factors are highlighted including high research and development roles and costs, hard government regulation in frame of gmp standard, market analysis tool...

This company produced intermediate compounds for the cosmetic and the pharmaceutical industries, including benzyl chloride and cyanide phenolacetic acid and 2,4,5 – trichlorophenol (TCP) – a toxic inflammable compound used as a bactericide and herbicide. It has been calculated that more than 1500 Kg of mixture went into the atmosphere including some Kg of pure 2,3,7,8 tetrachlorodibenzo-p-dioxi...

This has developed due to the limited number of licensed products available to treat dermatology conditions. Over time local dermatologists — with support from local pharmacy-manufacturing units — have created a number of unique topical preparations. These are widely used by dermatologists but never scrutinised under research conditions; similarly, it is unlikely that any pharmaceutical company...